The University of Southampton
University of Southampton Institutional Repository

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study
Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study
The aims of this study were to describe the variability in protein binding of teicoplanin in critically ill patients as well as the number of patients achieving therapeutic target concentrations. This report is part of the multinational pharmacokinetic DALI Study. Patients were sampled on a single day, with blood samples taken both at the midpoint and the end of the dosing interval. Total and unbound teicoplanin concentrations were assayed using validated chromatographic methods. The lower therapeutic range of teicoplanin was defined as total trough concentrations from 10 to 20 mg/L and the higher range as 10–30 mg/L. Thirteen critically ill patients were available for analysis. The following are the median (interquartile range) total and free concentrations (mg/L): midpoint, total 13.6 (11.2–26.0) and free 1.5 (0.7–2.5); trough, total 11.9 (10.2–22.7) and free 1.8 (0.6–2.6). The percentage free teicoplanin for the mid-dose and trough time points was 6.9% (4.5–15.6%) and 8.2% (5.5–16.4%), respectively. The correlation between total and free antibiotic concentrations was moderate for both the midpoint (ρ = 0.79, P = 0.0021) and trough (ρ = 0.63, P = 0.027). Only 42% and 58% of patients were in the lower and higher therapeutic ranges, respectively. In conclusion, use of standard dosing for teicoplanin leads to inappropriate concentrations in a high proportion of critically ill patients. Variability in teicoplanin protein binding is very high, placing significant doubt on the validity of total concentrations for therapeutic drug monitoring in critically ill patients.
0924-8579
423-430
Roberts, J.A.
fccbe098-1480-4c19-9742-09f00b3d3b4a
Stove, V.
10f7045f-525b-4932-a6c0-4a43ee49e4d6
De Waele, J.J.
c6b5c72e-cac7-451b-bb98-9d1a1ba1f8ca
Sipinkoski, B.
15461dba-a38a-4221-a5a5-317023e32c55
McWhinney, B.
48b4ec47-7dff-42b1-a91f-903bfc4201ab
Ungerer, J.P.J.
42b1527a-089d-4d40-bacb-52c72ef8a5a5
Akova, M.
4b98aac5-05ee-4265-81df-55909b4747ac
Bassetti, M.
69989d46-a7bf-4230-adbe-f2320d1a0202
Dimopoulos, G.
388a060e-faae-48d3-9533-3ac4d5825cab
Kaukonen, K.-M.
bcf8788f-679a-48e1-84a8-231c01c84fbf
Koulenti, D.
2ac3d761-49e2-4927-bdaa-f75f75d43cf5
Martin, C.
4ea95ba3-6ec8-4c6a-9a18-fcdc449ce4f7
Montravers, P.
eef1e2db-fdf1-4c29-a0c1-f143f5e1776b
Rello, J.
abad1dd1-6169-46d6-b477-823d66d98ccc
Rhodes, A.
f3418b79-08bb-4669-ba30-5e3b87419299
Starr, T.
89636156-3485-47d7-99c7-6e0e1ebc6253
Wallis, S.C.
2bd0fc55-8e8e-4996-9810-6f5f9716b92a
Lipman, J.
065a91d6-6087-48a6-9088-31a590c23dcc
Paul, S.
cdc9e984-cc17-4067-bb59-683806b65eb2
Ribas, A.M.
2268c4be-3573-4b45-9441-dc5c2e4b568d
DeCrop, L.
3750183a-6347-449a-9e08-f15591b542a5
Spapen, H.
e4889fb7-315e-4a76-ade6-95ca2a8f7b37
Wauters, J.
d669283a-29e4-454d-afab-51638c96b167
Dugernier, T.
033f0f05-75af-4beb-bfcf-030863802db0
Jorens, P.
2108b64a-c647-4267-a6e2-a03b439b07d4
Dapper, I.
6592cc36-72fd-4002-be16-a201a9d12641
De Backer, D.
d9773fee-371c-4148-8c35-dd21ba4db08e
Taccone, F.S.
d5bc5d9e-da19-4615-970e-7a88f0101d6e
Ruano, L.
5cc5ecc3-79b8-4224-b33a-718516f5407c
Afonso, E.
5360743b-8b8a-40af-8f03-4ca62d903636
Alvarez-Lerma, F.
a31a1d43-07e4-4584-ad5e-f491cca02543
Gracia-Arnillas, M.P.
ad4fa379-363b-4c6b-8f32-1483f5bdfacd
Fernández, F.
6f8d2bc7-221b-49f5-900d-69a091d2f4b6
Feijoo, N.
419e8eca-89f9-4ec5-9581-d8c7220191d5
Bardolet, N.
98ecfd93-68d8-419c-a4c4-73d8951e45b4
Rovira, A.
808cc7a7-ce25-4d26-a3a6-7fd9ac45d2c7
Garro, P.
7569b0e1-c95c-427e-9a86-efc3909d37ae
Colon, D.
17540d63-6e99-4477-9a6b-0854d0342412
Castillo, C.
cfdf4438-0c3f-421c-a4c3-f96719e744cb
Fernado, J.
063345ea-145a-404c-a112-f961559a7af1
Lopez, M.J.
f4ae622c-844a-45ee-87f1-668523df47e3
Fernandez, J.L.
7dfada4c-c61d-4429-a72a-0a878dbccf6a
Arribas, A.M.
d84cdb1c-c80b-4fa1-95d3-10e7a33fad38
Teja, J.L.
ff920a56-15f2-44a9-a6b1-3b41720c1ddd
Ots, E.
43c3609d-ff07-4a6f-a4e1-57610723b213
Montejo, J.C.
d1966cae-68a1-4c31-a02a-924301501fc0
Catalan, M.
13b78ceb-cd4f-4b74-9d02-5d6986b3154a
Prieto, I.
4d3ccaff-8f2a-48de-9440-81ec7050e06a
Gonzalo, G.
d446da3e-fb3b-433f-8c8f-65a0c4878540
McKenzie, C.
ec344dee-5777-49c5-970e-6326e82c9f8c
DALI Authors
Roberts, J.A.
fccbe098-1480-4c19-9742-09f00b3d3b4a
Stove, V.
10f7045f-525b-4932-a6c0-4a43ee49e4d6
De Waele, J.J.
c6b5c72e-cac7-451b-bb98-9d1a1ba1f8ca
Sipinkoski, B.
15461dba-a38a-4221-a5a5-317023e32c55
McWhinney, B.
48b4ec47-7dff-42b1-a91f-903bfc4201ab
Ungerer, J.P.J.
42b1527a-089d-4d40-bacb-52c72ef8a5a5
Akova, M.
4b98aac5-05ee-4265-81df-55909b4747ac
Bassetti, M.
69989d46-a7bf-4230-adbe-f2320d1a0202
Dimopoulos, G.
388a060e-faae-48d3-9533-3ac4d5825cab
Kaukonen, K.-M.
bcf8788f-679a-48e1-84a8-231c01c84fbf
Koulenti, D.
2ac3d761-49e2-4927-bdaa-f75f75d43cf5
Martin, C.
4ea95ba3-6ec8-4c6a-9a18-fcdc449ce4f7
Montravers, P.
eef1e2db-fdf1-4c29-a0c1-f143f5e1776b
Rello, J.
abad1dd1-6169-46d6-b477-823d66d98ccc
Rhodes, A.
f3418b79-08bb-4669-ba30-5e3b87419299
Starr, T.
89636156-3485-47d7-99c7-6e0e1ebc6253
Wallis, S.C.
2bd0fc55-8e8e-4996-9810-6f5f9716b92a
Lipman, J.
065a91d6-6087-48a6-9088-31a590c23dcc
Paul, S.
cdc9e984-cc17-4067-bb59-683806b65eb2
Ribas, A.M.
2268c4be-3573-4b45-9441-dc5c2e4b568d
DeCrop, L.
3750183a-6347-449a-9e08-f15591b542a5
Spapen, H.
e4889fb7-315e-4a76-ade6-95ca2a8f7b37
Wauters, J.
d669283a-29e4-454d-afab-51638c96b167
Dugernier, T.
033f0f05-75af-4beb-bfcf-030863802db0
Jorens, P.
2108b64a-c647-4267-a6e2-a03b439b07d4
Dapper, I.
6592cc36-72fd-4002-be16-a201a9d12641
De Backer, D.
d9773fee-371c-4148-8c35-dd21ba4db08e
Taccone, F.S.
d5bc5d9e-da19-4615-970e-7a88f0101d6e
Ruano, L.
5cc5ecc3-79b8-4224-b33a-718516f5407c
Afonso, E.
5360743b-8b8a-40af-8f03-4ca62d903636
Alvarez-Lerma, F.
a31a1d43-07e4-4584-ad5e-f491cca02543
Gracia-Arnillas, M.P.
ad4fa379-363b-4c6b-8f32-1483f5bdfacd
Fernández, F.
6f8d2bc7-221b-49f5-900d-69a091d2f4b6
Feijoo, N.
419e8eca-89f9-4ec5-9581-d8c7220191d5
Bardolet, N.
98ecfd93-68d8-419c-a4c4-73d8951e45b4
Rovira, A.
808cc7a7-ce25-4d26-a3a6-7fd9ac45d2c7
Garro, P.
7569b0e1-c95c-427e-9a86-efc3909d37ae
Colon, D.
17540d63-6e99-4477-9a6b-0854d0342412
Castillo, C.
cfdf4438-0c3f-421c-a4c3-f96719e744cb
Fernado, J.
063345ea-145a-404c-a112-f961559a7af1
Lopez, M.J.
f4ae622c-844a-45ee-87f1-668523df47e3
Fernandez, J.L.
7dfada4c-c61d-4429-a72a-0a878dbccf6a
Arribas, A.M.
d84cdb1c-c80b-4fa1-95d3-10e7a33fad38
Teja, J.L.
ff920a56-15f2-44a9-a6b1-3b41720c1ddd
Ots, E.
43c3609d-ff07-4a6f-a4e1-57610723b213
Montejo, J.C.
d1966cae-68a1-4c31-a02a-924301501fc0
Catalan, M.
13b78ceb-cd4f-4b74-9d02-5d6986b3154a
Prieto, I.
4d3ccaff-8f2a-48de-9440-81ec7050e06a
Gonzalo, G.
d446da3e-fb3b-433f-8c8f-65a0c4878540
McKenzie, C.
ec344dee-5777-49c5-970e-6326e82c9f8c

Roberts, J.A., Stove, V. and De Waele, J.J. , DALI Authors (2014) Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. International Journal of Antimicrobial Agents, 43 (5), 423-430. (doi:10.1016/j.ijantimicag.2014.01.023).

Record type: Article

Abstract

The aims of this study were to describe the variability in protein binding of teicoplanin in critically ill patients as well as the number of patients achieving therapeutic target concentrations. This report is part of the multinational pharmacokinetic DALI Study. Patients were sampled on a single day, with blood samples taken both at the midpoint and the end of the dosing interval. Total and unbound teicoplanin concentrations were assayed using validated chromatographic methods. The lower therapeutic range of teicoplanin was defined as total trough concentrations from 10 to 20 mg/L and the higher range as 10–30 mg/L. Thirteen critically ill patients were available for analysis. The following are the median (interquartile range) total and free concentrations (mg/L): midpoint, total 13.6 (11.2–26.0) and free 1.5 (0.7–2.5); trough, total 11.9 (10.2–22.7) and free 1.8 (0.6–2.6). The percentage free teicoplanin for the mid-dose and trough time points was 6.9% (4.5–15.6%) and 8.2% (5.5–16.4%), respectively. The correlation between total and free antibiotic concentrations was moderate for both the midpoint (ρ = 0.79, P = 0.0021) and trough (ρ = 0.63, P = 0.027). Only 42% and 58% of patients were in the lower and higher therapeutic ranges, respectively. In conclusion, use of standard dosing for teicoplanin leads to inappropriate concentrations in a high proportion of critically ill patients. Variability in teicoplanin protein binding is very high, placing significant doubt on the validity of total concentrations for therapeutic drug monitoring in critically ill patients.

This record has no associated files available for download.

More information

Accepted/In Press date: 23 January 2013
e-pub ahead of print date: 22 February 2014
Published date: 2014

Identifiers

Local EPrints ID: 479366
URI: http://eprints.soton.ac.uk/id/eprint/479366
ISSN: 0924-8579
PURE UUID: 2a506cb7-f664-497e-9000-0febe366f623
ORCID for C. McKenzie: ORCID iD orcid.org/0000-0002-5190-9711

Catalogue record

Date deposited: 20 Jul 2023 17:35
Last modified: 17 Mar 2024 04:23

Export record

Altmetrics

Contributors

Author: J.A. Roberts
Author: V. Stove
Author: J.J. De Waele
Author: B. Sipinkoski
Author: B. McWhinney
Author: J.P.J. Ungerer
Author: M. Akova
Author: M. Bassetti
Author: G. Dimopoulos
Author: K.-M. Kaukonen
Author: D. Koulenti
Author: C. Martin
Author: P. Montravers
Author: J. Rello
Author: A. Rhodes
Author: T. Starr
Author: S.C. Wallis
Author: J. Lipman
Author: S. Paul
Author: A.M. Ribas
Author: L. DeCrop
Author: H. Spapen
Author: J. Wauters
Author: T. Dugernier
Author: P. Jorens
Author: I. Dapper
Author: D. De Backer
Author: F.S. Taccone
Author: L. Ruano
Author: E. Afonso
Author: F. Alvarez-Lerma
Author: M.P. Gracia-Arnillas
Author: F. Fernández
Author: N. Feijoo
Author: N. Bardolet
Author: A. Rovira
Author: P. Garro
Author: D. Colon
Author: C. Castillo
Author: J. Fernado
Author: M.J. Lopez
Author: J.L. Fernandez
Author: A.M. Arribas
Author: J.L. Teja
Author: E. Ots
Author: J.C. Montejo
Author: M. Catalan
Author: I. Prieto
Author: G. Gonzalo
Author: C. McKenzie ORCID iD
Corporate Author: DALI Authors

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×